Cargando…

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

SIMPLE SUMMARY: GD2 is an antigen that is tumor-specific and can be used as a target for specific immunotherapies. Since the knowledge about GD2 in breast cancer is limited, we analyzed the frequency of GD2 expression in breast cancer using two different staining methods and the impact of GD2 expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erber, Ramona, Kailayangiri, Sareetha, Huebner, Hanna, Ruebner, Matthias, Hartmann, Arndt, Häberle, Lothar, Meyer, Julia, Völkl, Simon, Mackensen, Andreas, Landgraf, Laura, Geppert, Carol I., Schulz-Wendtland, Rüdiger, Beckmann, Matthias W., Fasching, Peter A., Farwick, Nicole, Rossig, Claudia, Gass, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582848/ https://www.ncbi.nlm.nih.gov/pubmed/34771738 http://dx.doi.org/10.3390/cancers13215577

Ejemplares similares

PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer
por: Erber, Ramona, et al.
Publicado: (2020)

HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
por: Wuerfel, Franziska M., et al.
Publicado: (2020)

Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis
por: Schulmeyer, Carla E., et al.
Publicado: (2023)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
por: Wu, Dianna Y., et al.
Publicado: (2003)

Mammographic density and prognosis in primary breast cancer patients
por: Heindl, Felix, et al.
Publicado: (2021)

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
por: Rossig, Claudia, et al.
Publicado: (2018)

The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies
por: Holterhus, Malcolm, et al.
Publicado: (2022)

The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer
por: Ranjan, Raphela A., et al.
Publicado: (2023)

Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients
por: Hein, Alexander, et al.
Publicado: (2014)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
por: Kailayangiri, Sareetha, et al.
Publicado: (2020)

Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2
por: Müller, Jan, et al.
Publicado: (2016)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin
por: Inagaki, Fuyuki F., et al.
Publicado: (2022)

HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells
por: Altvater, Bianca, et al.
Publicado: (2021)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
por: Pöschke, Patrik, et al.
Publicado: (2023)

Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data
por: Wunderle, Marius, et al.
Publicado: (2018)

Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound
por: Häberle, Lothar, et al.
Publicado: (2017)

Surface expression of the immunotherapeutic target G(D2) in osteosarcoma depends on cell confluency
por: Wiebel, Malena, et al.
Publicado: (2021)

Disialoganglioside GD2 distributes preferentially into substrate- associated microprocesses on human melanoma cells during their attachment to fibronectin
Publicado: (1986)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G
por: Spurny, Christian, et al.
Publicado: (2017)

Feasibility and Acceptance of Self-Guided Mobile Ultrasound among Pregnant Women in Routine Prenatal Care
por: Pontones, Constanza A., et al.
Publicado: (2023)

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients
por: Huebner, Hanna, et al.
Publicado: (2018)

Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD(2) Coated Nanoparticles
por: Tivnan, Amanda, et al.
Publicado: (2012)

RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women
por: Wunderle, Marius, et al.
Publicado: (2020)

An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2
Publicado: (1987)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy
por: Schrauder, Michael G., et al.
Publicado: (2019)

Predicting mammographic density with linear ultrasound transducers
por: Behrens, Annika, et al.
Publicado: (2023)

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians
por: Gass, Paul, et al.
Publicado: (2018)

Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments
por: Gsottberger, Franziska, et al.
Publicado: (2021)

Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
por: Gebrekidan, Medhanie Tesfay, et al.
Publicado: (2018)

The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
por: Gao, Yang, et al.
Publicado: (2015)

Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
por: Gao, Yang, et al.
Publicado: (2016)

Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
por: Erber, Ramona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sbqotosv5hcrvigkqd61ck5tg0